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As experience is gained with toxicology testing and as new assays and technologies are developed, it is
critical for stakeholders to discuss opportunities to advance our overall testing strategies. To facilitate
these discussions, a workshop on practices for assessing immunotoxicity for environmental chemicals
was held with the goal of sharing perspectives on immunotoxicity testing strategies and experiences,
developmental immunotoxicity (DIT), and integrated and alternative approaches to immunotoxicity test-
ing. Experiences across the chemical and pharmaceutical industries suggested that standard toxicity
studies, combined with triggered-based testing approaches, represent an effective and efﬁcient approach
to evaluate immunotoxic potential. Additionally, discussions on study design, critical windows, and new
guideline approaches and experiences identiﬁed important factors to consider before initiating DIT eval-
uations including assay choice and timing and the impact of existing adult data. Participants agreed that
integrating endpoints into standard repeat-dose studies should be considered for fulﬁlling any immuno-
toxicity testing requirements, while also maximizing information and reducing animal use. Participants
also acknowledged that in vitro evaluation of immunosuppression is complex and may require the use of
multiple assays that are still being developed. These workshop discussions should contribute to develop-
ing an effective but more resource and animal efﬁcient approach for evaluating chemical
immunotoxicity.
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Evaluation of immunotoxicity is an important component of the
hazard evaluation and safety assessment process for both pharma-
ceuticals and environmental chemicals, including pesticides.
Although standard toxicity studies provide valuable data for eval-
uating immunotoxicity, endpoints such as organ weights, histopa-
thology, hematology, and additional endpoints that involve
characterization of the cellular and functional status of the im-
mune system can provide additional information for the assess-
ment of immunotoxic potential. Such studies may include
assessment of the ability to respond to immunization (e.g., the T-
cell dependent antibody response (TDAR)), the capacity to destroy
neoplastic cells (e.g., the natural killer (NK) cell assay), the relative
abundance of lymphocyte subpopulations, or a variety of other
functional and observational assays. Due to the additional informa-
tion these studies can provide, immunotoxicity testing guidance
has been developed for pharmaceuticals and environmental chem-
icals, although with different requirements for incorporation into
their respective testing paradigms (ICH, 2005; US EPA, 2007). Un-
der chemical regulations, pesticide registrations require the com-
pletion of a substantial number of toxicity studies with a recent
additional requirement for the conduct of speciﬁc immunotoxicity
assays (US EPA, 2007). In contrast, guidance for pharmaceuticals
uses a weight of evidence (WoE) approach that only requires spe-
ciﬁc immunotoxicity assays if there is cause for concern identiﬁed
in standard toxicity studies.
While animal toxicity testing is a critical component for assess-
ing the hazard potential of both environmental and pharmaceuti-
cal chemicals, it is recognized that the approach is time-
consuming, expensive, requires extensive use of animals, and
may not take full advantage of emerging technologies and biolog-
ical knowledge. Such sentiments are conveyed in the National Re-
search Council (NRC) report entitled: ‘‘Toxicity Testing in the 21st
Century: A Vision and a Strategy’’ (NRC, 2007). This report has
highlighted a potential strategy to move away from animal-fo-
cused testing to an approach that uses high-throughput methods
with in vitro human model systems. While it will take years for
such a vision to be completely developed, evaluated and effectively
implemented, it has provided increased focus and discussion on
the need for improving both the efﬁciency and effectiveness of
our current testing approaches (Andersen and Krewski, 2010). In
the shorter term, there are opportunities to reﬁne our approaches
to toxicity testing through progressive tiered-evaluation ap-
proaches and integrated testing approaches that can be used to re-
ﬁne and optimize animal use and data generation. Similarly,
retrospective analyses can be valuable approaches to evaluate
the impact of current testing strategies as a means to prioritize
areas for improvement, guide and support changes in current data
requirements and study designs, and to enhance our approaches to
data interpretation and utilization. Recent examples that are rele-
vant for pesticides include analyses and discussions on the one-
year dog study requirement (Dellarco et al., 2010), the two-gener-
ation rat reproductive study (Piersma et al., 2011; Rorije et al.,
2011), and the mouse carcinogenicity study (Billington et al.,
2010).
As additional experience is gained with current testing require-
ments and as new assays and technologies are developed, it is crit-
ical for all stakeholders to engage in active dialog about potential
opportunities to advance our current testing approaches. To facili-
tate these discussions in the area of immunotoxicology, a work-
shop hosted by the International Life Sciences Institute-Health
and Environmental Sciences Institute (ILSI–HESI) was held on the
evaluation of current practices for the assessment of immunotoxic-
ity for environmental chemicals. The goal of this workshop was toshare current perspectives from experts in the ﬁeld on approaches
for the assessment of immunotoxicity, with a focus on immuno-
suppression. Diverse perspectives were captured from various sec-
tors to ensure a broad consideration of different approaches and
experiences with the use of standard endpoints and functional as-
says, as well as tiered-based testing strategies and developing as-
says and study designs. Major themes of the workshop included
discussions on current immunotoxicity assessment strategies and
experiences, developmental immunotoxicity assessment, and inte-
grated and alternative approaches to immunotoxicity testing.
What follows is a summary of the key messages and discussions
in these areas that took place during the workshop.2. Current immunotoxicology assessment approaches and
experiences
Immunotoxicity is a term used to describe the alteration of the
normal structure and/or function of the immune system as deter-
mined by established immunological and toxicological approaches.
Studies in laboratory animals have provided information on the
types of immunotoxic effects that chemicals may induce, and that
information has been used to assess the sensitivity and predictabil-
ity of toxicological testing approaches for the identiﬁcation of
immunotoxicity (Luster et al., 1988; Luster et al., 1992a; Luster
et al., 1993; Vos and Van Loveren, 1987). In 1979, under the aus-
pices of the United States National Toxicology Program (US NTP),
a panel of experts gathered to prioritize a list of immunological as-
says that would be suitable for use in rodent toxicology studies.
Four laboratories participated in the ensuing validation effort to
determine whether the tests selected by the panel had the required
sensitivity and reproducibility to successfully detect subtle altera-
tions in immune function and host resistance in mice (Luster et al.,
1988). Subsequent studies used this testing panel to evaluate
approximately 50 chemicals and established correlations between
speciﬁc immune function and host resistance tests (Luster et al.,
1993; Luster et al., 1992b). In addition to these comprehensive
examinations with mouse models, the rat has also been a focus
in immunotoxicity testing, primarily because of its standardized
use in preclinical toxicity studies. In the late 1970s, a testing panel
using the rat based on the Organisation for Economic Cooperation
and Development (OECD) 407 guideline was developed at the
Dutch National Institute of Public Health and the Environment
(RIVM) (van Loveren and Vos, 1989; Vos, 1977; Vos, 1980). The
utility of the rat model for immunotoxicity testing was further
evaluated and validated through a number of inter-laboratory
studies with known immunosuppressive agents (ICICIS Group
Investigators, 1998; Richter-Reichhelm et al., 1995; White, 1992).
Over time, the screening paradigms from both the NTP and RIVM
have been updated to include additional endpoints, such as ‘‘en-
hanced histopathology’’ and routine enumeration of lymphocyte
subsets, and new techniques (particularly in vitro methods) are
continuously being considered and evaluated for their utility as
predictors of potential toxicity to the immune system. Importantly,
the early work from these groups, in terms of immunotoxicology
assay development, evaluation and implementation, played a crit-
ical role in shaping the development of immunotoxicology guide-
lines for both pharmaceuticals and environmental chemicals.2.1. Pharmaceutical industry guidelines for immunotoxicity and
experience
Guidelines for the assessment of the immunotoxicity of phar-
maceuticals emerged independently and differently within the
European Union (EU) and the United States. The EU Committee
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all new chemical entities for their potential to cause adverse effects
on the immune system and immune function in preclinical species
(Gore, 2006). These studies were required in addition to the stan-
dard toxicology studies (STS) and included immunological assays
such as lymphocyte phenotyping, NK cell assays and the TDAR as-
say. In contrast, the US Food and Drug Administration (FDA) used a
‘‘cause for concern’’ approach, where the results from STS were
used to provide evidence of the potential for immunotoxicity
which, if identiﬁed, would be followed up with additional studies,
including functional immunotoxicity assays.
While both agencies supported a tiered approach in which any
initial evidence of immunotoxicity would be followed up with
additional immunological studies, the differences in the manda-
tory requirement for speciﬁc immunological studies between the
agencies prompted action by the International Conference on Har-
monization (ICH) to discuss potential harmonization of immuno-
toxicity testing requirements. This decision led to the formation
of an Immunotoxicology Expert Working Group whose objective
was to develop best practices for assessment of unintended immu-
nosuppression (Weaver et al., 2005). A research project was initi-
ated to review the correlation between STS and functional
immune assays. The consensus output from this analysis was that
routine testing, with speciﬁc studies that evaluate immune func-
tion, for all new drugs did not offer signiﬁcant additional informa-
tion beyond the STS and should not be a mandatory testing
requirement. This opinion and associated recommendations were
subsequently implemented into the ICH S8 guidance on immuno-
toxicity studies for human pharmaceuticals (ICH, 2005).
The ICH S8 guidance states that ‘‘all new human pharmaceuti-
cals should be evaluated for the potential to produce immunotox-
icity’’. The foundations of this evaluation are the test results from
the STS, which contain numerous immune system endpoints
(e.g., clinical signs of infection, hematologic evidence of inﬂamma-
tion or cytopenias, globulin levels, changes in bone marrow or lym-
phoid tissue, inﬂammatory inﬁltrates or pathogenic/opportunistic
organisms seen in tissues). No single parameter is enough to rule
immunotoxicity ‘‘in’’ or ‘‘out’’; all parameters should be considered
together in a WoE approach to determine if there may be an effect
on the immune system. The review of the STS data, in conjunction
with other factors, may prompt additional testing. The guidance
lists six factors that should be considered in the evaluation of po-
tential immunotoxicity (Table 1). These factors are to be assessed
in a WoE approach to determine if a cause for concern exists. A
ﬁnding of sufﬁcient magnitude in a single area should trigger func-
tional immunotoxicity studies. As part of the guideline, the evalu-
ation of the immunotoxic potential of a pharmaceutical has been
structured using a decision tree approach. The established ap-
proach would not lead to a blockade for development of the phar-
maceutical compound if the potential for immunotoxicity was
identiﬁed; however, it provides a signal to be included in the risk
assessment/management approach in the clinical situation. This
approach was perceived as an important step forward for putting
the immunotoxicological ﬁndings into a translational perspective.Table 1
Summary of the ICHS8 guideline factors to consider in the evaluation of potential Immun
Factor Context
Standard toxicity studies Are there signs of immunotoxic potential b
Pharmacological properties Do the pharmacological properties of a tes
inﬂammatory drugs)?
Intended patient population Is the intended patient population already
Structural similarity Is there structural similarity to other know
Disposition of the drug Is the drug retained at high concentrations
Signs observed in clinical trials or
clinical use
Did clinical ﬁndings or signs suggest potenIn practice, the ICH S8WoE approach to immunotoxicity assess-
ment has proven to be a practical yet science-based approach to
pharmaceutical risk assessment. STS, which are the foundation of
the guidance, have many endpoints which assess the immune sys-
tem from different perspectives and follow-up studies should be
selected based on speciﬁc concerns determined in a WoE review.
In practice, one potential controversial area for the assessment of
immunotoxicity is the contribution of stress responses to lymphoid
changes. The ICH S8 appropriately cautions against dismissing
such effects without the appropriate scientiﬁc rationale. The re-
lease of endogenous corticosteroids under stressful conditions
can inﬂuence lymphocyte trafﬁcking, production, and survival.
However, without corroborating evidence of ‘‘stress,’’ a direct ef-
fect on the immune system should be considered. Stress-related
changes to immunological endpoints in STS can usually be differ-
entiated from direct immunotoxicity through various indicators,
including signs of increased endogenous corticosteroid release
(e.g., stress leukogram of neutrophilia and lymphopenia, hypergly-
cemia, and adrenal cortex hyperplasia) and ﬁndings suggesting
overt toxicity (e.g., anorexia, weight loss, decreased body weight
gain, hunched appearance, organ failure). If the WoE review sug-
gests a need for immunotoxicity assessment beyond STS, studies
are conducted to determine the mechanism, the no observed ad-
verse effect level (NOAEL), potential reversibility, translation to hu-
man risk, and overall product marketability. In some instances this
review may also be a trigger to screen back-up or alternative can-
didate molecules. Experience has shown that few molecules dem-
onstrate sufﬁcient cause for concern to trigger the second tier of
testing (i.e., beyond STS). Of these, very few have been found to
be immunotoxic in humans, or are discontinued from development
due to immunotoxicity concerns (Bugelski et al., 2010; Weaver
et al., 2005).
2.2. Chemical industry guidelines for immunotoxicity and experience
Exposure scenarios for drugs and chemicals are quite different.
In the case of pharmaceuticals, therapeutic exposure is typically
well-understood, a risk/beneﬁt assessment for the individual pa-
tient can be conducted, and individuals are monitored, with any ef-
fects documented, in human clinical trials. In contrast, chemical
regulations mandate minimizing or preventing human exposure
to ensure the chemicals do not pose an unreasonable risk to health
and the environment. For the chemical industry, only pesticides
have speciﬁc regulations and there are extensive data require-
ments that are used in pesticide hazard evaluation and risk assess-
ment. In 1989, the US Environmental Protection Agency (EPA)
Scientiﬁc Advisory Panel recommended evaluation of immunotox-
icity as a part of the hazard assessment process for pesticide regis-
trations. Subsequently, an immunotoxicity test guideline (OPPTS
870.7800) was developed and published (US EPA, 1998). Currently,
the US EPA is the only chemical regulatory agency to have speciﬁc
immunotoxicity testing requirements. The assessment of immuno-
toxicity became a part of the required studies in the revised 40 CFR
Part 158 Toxicology Data Requirements for conventional pesticideotoxicity.
ased on the result of previous toxicology studies?
t compound indicate it has the potential to affect immune function (e.g., anti-
in an immunocompromised state?
n immunotoxicants?
in cells of the immune system?
tial immunotoxicity?
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recently for antimicrobial pesticide registration (US EPA, 2013).
The immunotoxicity test guideline is intended to provide informa-
tion on suppression of the immune system which might occur as a
result of repeated exposure to a test chemical. These data are to be
used along with results from STS to provide more accurate infor-
mation on the risk to the immune system. The test methods are de-
signed to assess the TDAR to evaluate the functional
responsiveness of major components of the immune system to a
T-cell dependent antigen (e.g., sheep red blood cells (SRBC), with
either an antibody forming cell (AFC) assay or an enzyme linked
immunosorbent assay (ELISA)). In the event that the test substance
produces signiﬁcant suppression of the TDAR, phenotypic analysis
for lymphocyte subpopulations may be required to characterize
which cell types are affected by the test substance. If the test sub-
stance has no signiﬁcant effect on the TDAR, a functional test for
NK cell activity may be performed to evaluate the chemical’s effect
on non-speciﬁc (innate) immunity to ensure the integrity of the
immune system.
In 2009, EPA’s Ofﬁce of Pesticide Programs modiﬁed the above
immunotoxicity testing strategy in agreement with the registrants
and the pesticide stakeholders to simplify immunotoxicity testing.
The new strategy uses a WoE approach to determine the testing
needs beyond the TDAR study. For example, if the test substance
produces dose-related suppression of TDAR, then the test sub-
stance is considered immunotoxic and no further testing is re-
quired. On the other hand, if the TDAR is negative and there is
suggestive evidence of adverse effect on the immune system end-
points from the STS (e.g., changes in lymphoid organ weights,
hematology, or histopathology), an NK cell assay is required to
evaluate any effect on innate immune function. However, if there
is no evidence to suggest that the immune system is a primary tar-
get organ of the test substance, a functional NK cell assay may not
be necessary (Fig. 1).
Since this requirement came into effect, pesticide registrants
have completed and submitted more than 80 guideline-compliant
TDAR studies which provided an opportunity to evaluate the po-
tential implications of these required immunotoxicity studies on
hazard identiﬁcation and risk assessment. To assess the regulatory
impact, Crop Life America member companies participated in a ret-
rospective analysis that included a dataset of 82 immunotoxicity
studies conducted on a diverse set of 78 unique pesticide chemi-
cals (Gehen et al., submitted for publication; US EPA, 2013). This
dataset represented a wide distribution of product types and
chemical classes, and also included a balanced diversity in terms
of species, strains, gender and methods of TDAR quantitation to
help ensure that the results of the analysis did not arise from a nar-
row set of TDAR study conditions. The objective of the Crop Life
America analysis was to determine the frequency of positive assay
responses and the potential for the TDAR to impact hazard assess-
ment and human health risk assessment. The analysis revealed
that for 77 of 82 studies the TDAR was unaltered at all dose levels,
while in the remaining ﬁve studies, a reduction was observed but
only at the high-dose level (Gehen et al., submitted for publication;
US EPA, 2013). In all of the cases, a follow up NK assay was deemed
unnecessary by the chemical registrant based on the results from
the TDAR as well as the STS. To assess the impact of these data,
TDAR NOAELs were compared to the toxicity endpoints that were
previously selected for use in the speciﬁc pesticide risk assess-
ments. For all 78 chemicals, the TDAR NOAELs were greater than
the critical values selected for the existing risk assessments. Based
on this Crop Life America analysis, routine conduct of the TDAR as-
say appears to have had a limited impact on chemical pesticide
hazard identiﬁcation and human health risk assessment. These
data suggest that alternative approaches, that include an initial
WoE analysis for immunotoxic potential, should be consideredprior to conducting animal-based functional immunotoxicity test-
ing for chemical pesticides, similar to what is done for the hazard
assessment of pharmaceuticals.2.3. Opinions from workshop participants
Given the differences in the approaches and requirements for
chemicals and pharmaceuticals, discussions during the workshop
session on current immunotoxicology testing approaches and
experiences focused on consideration of whether characterization
of the immunotoxic potential of a chemical should be routinely
examined, or if there is sufﬁcient scientiﬁc knowledge to use a trig-
gered approach. All participants agreed that a trigger-based ap-
proach for environmental chemicals, as used for pharmaceuticals
under ICH S8 guidance, should be considered; however, partici-
pants also realized that deﬁned criteria need to be available to en-
sure the consistent and transparent interpretation of the potential
need for additional immunotoxicity testing. This assessment
should consist of a WoE assessment of the available data, including
that from STS, along with consideration of toxicokinetics, use pat-
terns, and the actual potential for exposure. Such an approach is
not unlike that provided in the ICH S8 guidance for pharmaceuti-
cals. Additional retrospective analyses may help to solidify the
appropriateness of this approach while also deﬁning the most
informative triggers that can be used as part of the risk assessment.
The participants also agreed that if additional immunotoxicity
testing is triggered, based on the initial WoE assessment, then
the assays selected for use should be those that have shown good
performance in terms of both sensitivity and speciﬁcity based on
previous validation and retrospective analyses. From a practical
standpoint, the assays should not be overly complex, to ensure
broad and reliable applicability across laboratories. Participants
also acknowledged that current data indicate that the TDAR is a
good starting point for assay consideration given that it is one of
the few immunotoxicological endpoints that requires many of
the cellular components of an immune response (e.g., B-cells, T-
cells, macrophages) and thus, is a sensitive indicator of a chemical’s
immunotoxic potential (Luster et al., 1992b). However, it was also
realized that assay selection for a speciﬁc chemical should also
consider ﬁndings from the existing data such that the studies can
be selected to address the identiﬁed cause for concern, as applica-
ble. Overall, participants agreed that these consensus points de-
serve further consideration and discussion through focused
assessments and expert consultations for implementation into an
approach for the assessment of immunotoxicity for chemicals
management.3. Assessment of developmental immunotoxicity
Over the last two decades there has been a growing interest in
establishing an increased understanding of age-related susceptibil-
ities to toxicity with considerable efforts devoted to understanding
potential differences between infants and children when compared
to adults. During this time, attention to DIT has grown signiﬁcantly
in scope. This interest is based on the concept that the developing
immune system may be qualitatively and/or quantitatively more
susceptible to xenobiotic perturbation when compared to the
adult. There have been numerous workshops, roundtables, sympo-
sia, and sponsored research to address questions pertaining to DIT
(i.e., triggers, protocols, endpoints and assays to measure DIT, haz-
ard identiﬁcation, and risk assessment) (Burns-Naas et al., 2008;
DeWitt et al., 2012; Dietert et al., 2000; Holsapple, 2002; Holsapple
et al., 2005; Holsapple et al., 2007; Ladics et al., 2005; Ladics et al.,
2000; Luster et al., 2003). One of the goals of this workshop was to
IMMUNOTOXIC
Weight of Evidence (WOE) review
Perform TDAR Assay (SRBC) in selected 
species
Negative
Reconsider WOE evaluation of 
repeat dose studies for evidence 
of immunotoxicity
Dose-related positive at <MTD
Some evidence (organ 
weights, hematology, 
histopathology)
Negative
Perform NK cell activity assay NOT IMMUNOTOXIC
NegativePositive at doses <MTD
Select most appropriate species (rat or mouse) and gender based on (1) 
structural change in immune system, or (2) general toxicity, or (3) default 
female mouse
Select most appropriate species (rat or mouse) and gender 
Based on WOE: (1) structural changes in immune system, then
(2) general toxicity.  If no effects, use female mice as default.
Fig. 1. EPA guidance for a weight of evidence (WoE) decision tree approach for immunotoxicity testing. The existing standard toxicity studies (STS) are ﬁrst reviewed for any
evidence of immunotoxicity that would help to identify the most sensitive species (rat/mouse) and gender for subsequent immunotoxicity testing. If no immunotoxic effects
are identiﬁed, general toxicity parameters are used to deﬁne the most sensitive species and gender, with the female mouse as the default in the absence of appropriate
toxicity discriminators. The TDAR is subsequently conducted in the most sensitive species and gender. If the test material produces a dose-related suppression of the TDAR, it
is considered ‘immunotoxic’ and no further testing is required. If the available STS and WoE suggest no potential for immunotoxicity, then no further testing is required and
the test material is considered ‘not immunotoxic’. However, if the data suggest some potential for effects on the immune system an NK cell assay may be required to further
characterize any immunotoxic potential. (MTD = maximum tolerated dose).
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approaches and considerations for the assessment of DIT.
3.1. Background on developmental immunotoxicity testing
The basic tenet behind the interest in assessing the risk to hu-
man development is that children differ signiﬁcantly from adults
in their biological and/or physiological responses to environmental
exposures (Holsapple et al., 2004). In the context of the develop-
ment of the human immune system, common infectious diseases
can occur more often, and are usually more severe in the very
young when compared to adolescents and adults, and infants are
more susceptible to immune toxicities and immune manipula-
tions. Yet, it is important to note that infants can mount a vigorous
immune response to tissue and organ allografts, and to vaccines
(i.e., there is immunocompetence in the very young).
In the context of DIT, the speciﬁc hypothesis to be considered is
that the developing immune system demonstrates greater suscep-
tibility to chemical perturbation than the adult immune system.
From a regulatory perspective, there is concern that a well-de-
signed guideline immunotoxicity study conducted in adult animals
could miss a potentially greater susceptibility associated with the
critical stages of development of the immune system. As noted
by Burns-Naas et al. (2008), this susceptibility can be manifest as
a qualitative difference (e.g., developing immune system affected,
but not the adult immune system), a quantitative difference (e.g.,
developing immune system affected at lower doses than the adult
immune system), or a temporal difference (e.g., effects on the
developing immune system are more persistent than those seen
with the adult immune system). Luebke et al. (2006) presentedevidence that these types of differences between the developing
and adult immune system have been identiﬁed through the
speciﬁc discussion of ﬁve example compounds.
From a scientiﬁc perspective, there has been a steadily increas-
ing interest in this topic with over 40 workshops, symposia, and
scientiﬁc sessions focused in-whole or in-large part on DIT since
2000. In particular, two workshops were organized in 2001 that
both took place in Washington, DC. The outcome from a workshop
organized by ILSI-HESI was summarized by Holsapple (2002), and
the outcome from a workshop organized by the NIEHS and the Na-
tional Institute for Occupational Safety and Health (NIOSH) was
summarized by Luster et al. (2003). While these two workshops
used different approaches, they addressed similar objectives, and
came forward with remarkably consistent conclusions and recom-
mendations, which included the following:
 Both permanent and transient effects should be considered.
 All critical stages of immune system development should be
assessed as part of a standard study design and speciﬁc stages
should be further studied, if an effect is seen.
 A DIT protocol could be extended to include juveniles and
young adults, as it is critical to continue exposure until possible
effects on the immune system can be assessed.
 Although the mouse is the primary animal model for immuno-
logical studies, and was the species used in the studies by Luster
et al. (1988, 1992b, 1993), the rat is considered to be the species
of choice for DIT studies (Holsapple, 2003) because of historical
experience and preference for rats in developmental and repro-
ductive toxicology (DART) studies (OECD, 1995; OECD, 1996).
However, it is important to consider the species differences in
“Classical”  DIT  ProtocolExposure to 
dams
Lactation
Young adult
8-10 weeks old
Immune
Test
Gd 0 Partuition Weaning
Gestation
“Alternative”  DIT  ProtocolExposure to 
dams
Gd 0 Partuition Weaning
= Immune Test
LactationGestation
“Proposed”  DIT  Protocol
Lactation 45 days & beyond
Gd 0 Partuition Weaning
Gestation
Exposure to 
dams
Immune
TestYoung
Adult
Exposure to 
pups +
No Treatment
(Recovery)
A
B
C
Fig. 2. Comparison of Multiple Protocols to Assess the Potential for DIT. The
‘Classical’ DIT Protocol (2A) depicts the state-of-the-science before and around
2000, in which pregnant dams were exposed under a variety of experimental
conditions – usually various periods of gestation – and the exposed F1 generation
was assessed for effects on the immune system when they became young adults,
the age at which these parameters had been optimized. An ‘Alternative’ DIT
Protocol (2B) was evaluated because of the possibility that the ‘Classical’ DIT
Protocol was primarily an assessment of the recovery of effects on the immune
system. The application of this protocol has been limited because of the relative
immaturity of the rodent immune system, when compared to the human immune
system (See Table 2). Based on the recommendations from two ‘benchmark’
workshops in 2001, a new DIT Protocol (2C) was ‘Proposed’ such that the exposure
extends to at least Day 42 to cover the juvenile stage.
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2003). This point is illustrated in Table 2 for the development
of the mouse and human immune systems, which clearly shows
that the development of the mouse immune system lags behind
that of the human immune system in the context of the full ges-
tation period for each species. Importantly, the developmental
timelines for the immune systems of the mouse and the rat
are similar.
The HESI workshop recognized that most ‘classical’ protocols to
assess the potential for DIT (e.g., those conducted prior to 2000)
used experimental designs in which pregnant dams were exposed
under a variety of experimental conditions (usually during some
period(s) of gestation) and the possible effects on the immune sys-
tem were assessed in the F1 generation when they became young
adults (Fig. 2A). This assessment approach was based on the fact
that immune tests had been optimized in young adult rodents.
Ladics et al. (2000) investigated an ‘alternative’ protocol for an
assessment of DIT (Fig. 2B), in which 10-day old and 21-day old
rats pups were evaluated using standard immune tests, such as
phenotyping and the TDAR. Their results served as a conﬁrmation
of the profound immaturity of the rodent immune system (Table 2),
when it was assessed shortly after parturition and/or weaning. In
light of these results, and the recommendations from both the HESI
workshop and the NIEHS/NIOSH workshop, it was proposed that
that all stages of development should be assessed under a single
study design and that it is critical to continue exposure until pos-
sible effects on the immune system can be assessed. From this, a
new DIT protocol was ‘proposed’ (Fig. 2C) in which pregnant dams
were exposed, and the exposure was continued until the F1 gener-
ation became young adults, at which time the immune tests were
conducted. The HESI workshop was the ﬁrst to recommend that
DIT study designs should be integrated into already required DART
protocols, to the extent possible. A subsequent paper by Ladics
et al. (2005) began to address the issues associated with including
neurotoxicology and immunotoxicology assessments in standard
DART studies. In spite of the recognized challenges associated with
this approach, it was concluded that a proposed framework for DIT
should be based on the integration of DIT study designs into stan-
dard DART protocols, to the extent possible (Holsapple et al., 2005).
This paper also emphasized that a proposed framework for DIT
should address all critical windows of development (e.g., in the
rat, evaluate a time point that allows for the assessment of any ef-
fects induced from gestation to postnatal day (PND) 45) and spe-
ciﬁc windows should be further studied if an effect is seen
(Fig. 2C). It was also emphasized that animals should be exposed
throughout the treatment protocol and that the triggers for assess-
ing DIT may include information from structure-activity relation-
ships, results from other toxicity studies, and a consideration of
the intended use of the drug or chemical.
The integration of immunotoxicity endpoints and functional as-
says into these studies has been accomplished in the so-called
‘‘juvenile pesticide studies,’’ as reported by Chapin et al. (1997)Table 2
Timing of immune system development in mice and humans.
Event M
Appearance of T cells in fetal liver 1
Organogenesis of thymus begins 1
Lymph nodes evident 1
Spleen develops 1
B cell lymphopoiesis begins in bone marrow 1
B lymphocytes detectable in blood 1
CD4+ and CD8+ T cells detectable in spleen 1
Thymus development completed 1
Bone marrow becomes the major site of hematopoiesis 1
T cell receptor expression in periphery Eand by Smialowicz et al. (2001), and was a critical element of the
HESI Agricultural Chemical Safety Assessment (ACSA) framework,
as described by Cooper et al. (2006). Importantly, the ACSA frame-
work became the basis for the OECD Test Guideline 443 study de-
sign (i.e., the so-called extended one-generation reproductive
toxicity study (EOGRTS)).3.1.1. OECD extended one-generation reproductive toxicity study
(EOGRTS)
A guideline approach for the evaluation of developmental
immunotoxicity is available through the conduct of the EOGRTS
(OECD, 2011c). The OECD Test Guidance 443 is based on initialouse (days) (% of term) Human (weeks) (% of term)
4 (67%) 6–8 (15–20%)
1 (52%) 6 (15%)
0.5 (50%) 8–12 (20–30%)
3 (62%) 10–14 (25–35%)
7 (81%) 12 (30%)
3 (62%) 12 (30%)
9 (91%) 14 (35%)
3 (62%) 15–16 (37–40%)
7.5 (83%) 22 (55%)
arly post-natal 23 (58%)
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HESI ACSA Technical Committee. The study assesses parental fertil-
ity and reproductive function and the development of offspring to
sexual maturity with an assessment of sexual landmarks. An eval-
uation of the developing nervous and/or immune system is also in-
cluded and a second generation can be triggered if any effects
requiring further evaluation are identiﬁed in the ﬁrst generation
(OECD, 2011b). The design provides the opportunity to evaluate
life stages not covered by other study types while minimizing
the use of experimental animals. Overall, the study represents a
highly integrated, and potentially logistically and technically com-
plicated, study design that includes an assessment of DIT.
Prior to the formal adoption of the guideline, studies were
undertaken by members of the European Crop Protection Associa-
tion to evaluate the draft study design for technical feasibility. In
addition, a study was conducted in response to a request by the
US EPA for reproduction and developmental neurotoxicity data.
The outcome of these studies has been summarized (Fegert et al.,
2012). An evaluation of immunotoxicity was included in some of
the studies reported and results for the studies on lead acetate
and 2,4-dichlorophenoxyacetic acid (2,4-D) are discussed below.
OECD 443 speciﬁes that determination of the primary IgM re-
sponse to a TDAR is required on PND 56 (±3 days) if the DIT option
is exercised. The antigens suggested are SRBC or keyhole limpet
hemocyanin (KLH), although the latter is not yet recognized by
US EPA as an acceptable antigen, and the evaluation methods spec-
iﬁed are AFC or serum antibody titers as measured by ELISA. The
draft OECD Guidance Document 151 (OECD, 2011a) discusses the
choice of appropriate antigen in more detail and highlights the po-
tential of investigating antibody class switching, a biological mech-
anism that changes a B cell’s antibody production from one class to
another (e.g., IgM to IgG), if deemed necessary.
The study design for OECD 443 includes a pre-mating treatment
period of 2–4 weeks followed by a mating period of 2 weeks. The
majority of mating would be expected to occur during the ﬁrst es-
trus cycle, but some pairs may mate during the second cycle. As a
result, littering (PND 0) would be expected to occur over at least 4,
and possibly 8, days assuming no effect of test substance on the
duration of the cycle or gestation length. The resulting variability
in the date at which each litter reaches PND 56 can complicate
TDAR assay conduct and may inﬂuence the choice of TDAR assay
undertaken (i.e., AFC assay or ELISA based approaches). The overall
integrated study design and associated complexity are depicted in
Fig. 3.
Two EOGRTSs that included immunotoxicity evaluations were
presented as part of the workshop, one with lead acetate and the
other with 2,4-D. The evaluation of lead acetate was conducted
in Wistar rats and included an evaluation of the T-cell dependent
IgM antibody response to SRBC using an ELISA approach. One ani-
mal/sex/litter was used (a total of 20/sex/group), with blood taken
on PND 70. The group mean values for serum anti-SRBC IgM indi-
cated a reduction in circulating anti-SRBC IgM in top dose males
(27% decrease relative to controls) while the positive control,
cyclophosphamide, demonstrated a greater than 95% decrease in
the response (Fegert et al., 2012). Previous developmental toxicity
studies with lead acetate (Bunn et al., 2001; IARC, 2006; Miller
et al., 1998) have demonstrated a modulation of select immune re-
sponses in both Fischer 344 and Sprague-Dawley rats; however, an
effect on the antibody response to KLH was not identiﬁed in these
studies, consistent with the lack of a signiﬁcant effect in the
EOGRTS evaluation. Importantly, this study demonstrated the ini-
tial feasibility for the conduct of DIT as a part of the EOGRTS.
The evaluation of 2,4-D was conducted with Sprague-Dawley
rats and included an evaluation of the TDAR to SRBC on PND 70–
74 using the AFC assay (10 animals/sex/group). In addition, an
evaluation of NK cell activity was conducted in 10 animals/sex/group on PND 87–93., All positive controls responded appropri-
ately and there was no evidence of 2,4-D related immunotoxicity
in the TDAR assay and the NK cell assay, consistent with previous
evaluations (Fegert et al., 2012; Marty et al., 2013). However, the
TDAR assay data was confounded by added temporal variability
across the dose groups due to the conduct of the assay on different
days which was not balanced by dose group due to litter assign-
ments and the deﬁned age windows for the study and this partic-
ular endpoint (PND 70–74). This confounding factor is a
disadvantage of using the AFC assay for evaluation of the TDAR re-
sponse, as the assay needs to be conducted immediately following
animal sacriﬁce (Ladics, 2007). Therefore, due to the study design
age constraints and the assay conduct constrains, a clear ‘‘day’’ ef-
fect was observed that was unbalanced across groups. While this
result did not impact the overall interpretation for the endpoint,
it highlighted the need for planning and ﬂexibility in the age win-
dow to ensure a more balanced assessment if using the AFC assay.
Overall, using the draft OECD 443 guideline, the EOGRTS has
been successfully conducted by several laboratories in the US
and Europe (Fegert et al., 2012). As part of the study designs, an
evaluation of DIT was included and examples of the TDAR assay
with SRBC, as measured by the AFC assay and ELISA approaches,
have been reviewed. The data suggest that for this study, the ELISA
assay offers the advantage that blood samples can be taken from
animals on the speciﬁed sampling dates and stored frozen allowing
samples to be analyzed concurrently for antibody levels. This ap-
proach reduces the logistical difﬁculties of this highly complex
study and eliminates temporal variability and the possibility of
an imbalance across groups introduced by the need to use fresh tis-
sue as required by the AFC assay. Bleeding and retaining animals
for further investigation of antibody switching is also possible
using the ELISA assay as interim blood samples can be taken with-
out sacriﬁcing the animal. The successful completion of these stud-
ies clearly highlights the feasibility of the conduct of the EOGRTS;
however, the logistical and technical complexity of the study de-
sign, along with the potential impact of the data for advancing
the risk assessment for the molecule, should be carefully consid-
ered prior to the request and/or conduct of the study.
3.2. Opinions from workshop participants
One of the objectives of this workshop was to provide a forum
in which participants could discuss the current state-of-the-sci-
ence of DIT. Speciﬁc questions on DIT were posed during several
breakout sessions to help guide the discussion. The ﬁrst question
considered the value or advantages and disadvantages of DIT vs.
adult testing. DIT was considered valuable by workshop members
in that it speciﬁcally covers multiple critical windows of immune
system development, and therefore, DIT was able to maximize sen-
sitivity to detect any potential immunotoxic effects. DIT also affor-
ded the opportunity to look at different developmental periods, if
necessary, as well as the prospect for integrated studies (e.g., OECD
443 EOGRTS) and the associated advantages of integrated assess-
ment of endpoints (i.e., concurrent evaluation of other endpoints
and the sensitivity of other developing systems such as the endo-
crine or nervous systems). The overall consensus of participants
was that if a DIT was conducted, there was no need to conduct a
separate immunotoxicology study with adult animals. Likewise, if
an adult immunotoxicology study was available, it was suggested
that additional information be considered to justify the need for
a DIT study (e.g., additional speciﬁc cause-for-concern or endocrine
activities).
A number of potential disadvantages or challenges associated
with conducting a DIT were noted, particularly the current limited
understanding of the relative sensitivity of the developing immune
system in rodents and humans. Other identiﬁed issues included
Dosing
Pre-mating Mating Post-Mating
P 2-weeks 2-weeks 6-weeks
P 2-weeks 2-weeks Pregnancy Lactation
F1 In-utero development Pre-weaning Post-weaning
Parental 
generation Cohort Designation Animals/Cohort
Sexual 
maturation
Approximate age at 
necropsy (weeks)
Target is 20 
litters per 
group
1A Reproductive 20M + 20F Yes 13
1B Reproductive 20M + 20F Yes 14 or 20-25 if triggered
2A Neurotoxicity 10M + 10F @ Yes 11-12
2B Neurotoxicity 10M + 10F @ No 3 
3 Immunotoxicity 10M + 10F @ Yes 8 
Surplus Spares No 3 
@ one per litter and representative of 20 litters in total where possible
Necropsy
P animals
Fig. 3. Study Schematic for the OECD 443 Extended One-Generation Reproductive Toxicity Study. This study design is intended to provide an evaluation of reproductive and
developmental effects that may occur as a result of pre- and postnatal chemical exposure as well as an evaluation of systemic toxicity in pregnant and lactating females and
young and adult offspring. In the assay, sexually-mature male and female rodents (parental (P) generation) are exposed to doses of the test substance starting 2 weeks before
mating and continuously through mating, gestation and pup weaning (F1 generation). At weaning, pups are selected and assigned to cohorts of animals for reproductive/
developmental toxicity testing (cohort 1), developmental neurotoxicity testing (cohort 2) and developmental immunotoxicity testing (cohort 3). The F1 offspring receive
further treatment with the test substance from weaning to adulthood. Clinical observations and pathology examinations are performed on all animals for signs of toxicity,
with special emphasis on the integrity and performance of the male and female reproductive systems and the health, growth, development and function of the offspring. Part
of cohort 1 (cohort 1B) may be extended to include an F2 generation; in this case, procedures for F1 animals will be similar to those for the P animals.
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and/or lactational transfer); a lack of global alignment of DIT test-
ing approaches and the need for conducting such studies; the lack
of a speciﬁc testing guideline; and a loss of context of the WoE data
associated with adult exposures from other toxicology studies.
The endpoints and assays to be conducted in a DIT study have
been discussed extensively (Burns-Naas et al., 2008; Holsapple
et al., 2005). Participants agreed that the age at the time of evalu-
ation is critical in determining which types of endpoints are to be
assessed. For example, prior to PND21, assessment of the TDAR is
not feasible, as the immune system is not fully developed. The
TDAR can be assessed, albeit not at optimized levels, at and after
PND21 (Ladics et al., 2000). Workshop members indicated that a
TDAR can be conducted successfully when animals are six to eight
weeks of age (i.e., PND 42–56) (Ladics et al., 2000). Some partici-
pants suggested that cell-mediated immunity (e.g., the cytotoxic
T-lymphocyte assay) and NK cells should also be evaluated in
young adult animals following exposure throughout all life stages.
A number of gaps or problems were also raised in regard to the
implementation and/or interpretation of DIT. Speciﬁcally, for DIT
purposes, an EOGRTS should not be viewed as a routine assay, as
it is already quite complex with multiple dose groups and end-
points. Therefore, if a DIT is required, a standalone DIT protocol
may be preferred. In addition, some participants questioned
whether there were any compounds known to be positive in a
DIT study but negative in an adult immunotoxicology study, as
the extent to which this was known to occur would help to further
deﬁne the value in the conduct of DIT studies. To date, few such
compounds have been identiﬁed (e.g., 2,3,7,8-tetrachlorodibenzo-
p-dioxin (Gehrs and Smialowicz, 1999; Smialowicz et al., 1994)).
Further discussion addressed factors and data that may provide
relevant triggers for conducting aDIT study. Participants agreed thatboth adult andDIT studies should be triggered by an initialWoE that
woulddetermineand consider theneedand impact of the studydata
(i.e., a cause for concern approach), unless conducting an EOGRTS
that includes the DIT option. The WoE considerations discussed for
DIT included: thexenobiotic and its intendeduse (i.e., is therepoten-
tial for exposure at earlier life stages?); absorption, distribution,
metabolism, and excretion data; effects observed in developmental
toxicology and/or multigenerational reproduction studies; and
adult immunotoxicity ﬁndings, if available. Some participants sug-
gested that the same information (i.e., triggers) evaluated for adults
should also be considered as triggers for a DIT study. Overall partic-
ipants agreed that DIT studies can play an important role in charac-
terization of immunotoxicity; however, the requests and designs for
this study should be made after careful consideration of the study
objectives and needs.4. Integrated and alternative approaches to immunotoxicity
testing
In addition to the presentation and discussion of regulatory
testing requirements and DIT, the workshop also addressed current
and emerging approaches that could be implemented to help fur-
ther inform immunotoxicity potential as part of chemical safety
assessments. To accomplish this goal, a focus was placed on the
application of new approaches and technologies that would pro-
vide additional data while reducing or replacing animal use.
Although many approaches and technologies may be available,
the workshop focused on the potential for the use of integrated
study designs and in vitro assays for the assessment of immunotox-
ic potential.
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Integrated testing strategies involve the assessment of multi-
ple endpoints within a single toxicity study and represent an
important approach for reducing animal use and streamlining
testing approaches. In the ﬁeld of immunotoxicology, research
has been conducted to explore the ability to integrate the TDAR
assay with SRBCs into a standard 90-day repeat dose toxicity
study. To understand the feasibility and scientiﬁc validity of such
an approach, a series of studies were conducted to address
whether injection with SRBC would alter clinical pathology val-
ues or prevent the detection of standard toxicological responses,
such as alterations in organ weights and histopathology. Two
chemicals were used in the evaluation: cyclophosphamide (CP),
a known immunosuppressive compound, and carbon tetrachlo-
ride (CT), a hepatotoxicant whose primary target is not the im-
mune system. Male CD rats (n = 10–16/group) were dosed
either with vehicle or CP by intraperitoneal injection (study 1)
or with vehicle or CT by oral gavage (study 2) for 30 or 90 days.
Six days prior to study termination, half of the animals from
each treatment group were injected with SRBCs for evaluation
of the TDAR response. The remaining animals from each dose
group served as the non-SRBC injected controls to allow for eval-
uation of the impact of SRBCs on the standard toxicological end-
points. At study termination, endpoints evaluated included
hematology/clinical chemistry, serum anti-SRBC antibody (ELISA),
organ weights and histopathology (brain, heart, liver, thymus,
kidneys, testes, spleen) and spleen cell number. Splenocyte sub-
populations were also determined by ﬂow cytometry following
CT exposure. The results indicated that injection of SRBC in rats
administered CP over 30 or 90 days did not alter hematology or
clinical chemistry parameters compared to rats not receiving
SRBC. With the expected exception of the spleen, SRBC adminis-
tration did not alter the weights or morphology of tissues rou-
tinely collected or spleen cell numbers. Furthermore, the
immunosuppressive effects of CP were not masked by the
administration of SRBC at either time point (Ladics et al., 1995).
Similar to the results with CP, the injection of SRBCs in rats
administered CT over 30 or 90 days did not alter hematology, clin-
ical chemistry, organ weights or histopathology, with the excep-
tion of the spleen, when compared to rats not receiving SRBC.
Injection with SRBC also had no effect on relative or absolute num-
bers of splenic lymphocyte populations. Furthermore, injection of
SRBC in either 30- or 90-day study animals did not mask or alter
the ability to characterize the mild hepatotoxic effects of CT on
endpoints, such as increased sorbitol dehydrogenase activity, liver
hypertrophy, or centrilobular fatty changes (Ladics et al., 1998).
The results of these studies support the conclusion that assessment
of the functional responsiveness of humoral immunity can be con-
ducted in animals from standard toxicity studies without altering
standard toxicological endpoints.
Complementary studies supporting this conclusion were com-
pleted in an independent laboratory using female Fischer 344 rats
that were treated with CP or vehicle and with or without SRBC
injections. In this examination, the impact of SRBC immunization
on spleen and thymus weights and histopathology was examined,
along with the ability to evaluate the spleen AFC assay response
and spleen histopathology in the same animal via spleen section-
ing approaches. Consistent with the previous evaluations, immuni-
zation with SRBCs did not impact organ weights. Histopathology of
the spleen and thymus were also unaffected, with the exception of
minor increases in the number of germinal centers in the spleen.
The AFC response in vehicle and CP treated rats was similar be-
tween whole spleen samples and sectioned spleen, which support
the ability to evaluate both spleen histopathology and the AFC re-
sponse in a single animal (Woolhiser et al., 2007).4.1.1. Opinions from workshop participants
In aggregate, these data clearly demonstrated that assessment
of immunosuppression, as measured by a variety of endpoints
(e.g., spleen histopathology; SRBC antibody response) can be suc-
cessfully performed simultaneously in repeated dose studies as
part of an integrated study design, without the need for a separate
evaluation using additional animals. Workshop participants agreed
that the application of integrated study designs should be consid-
ered in designing studies to fulﬁll requirements for the assessment
of immunotoxicity. Integration of assays to detect immunosup-
pression into existing testing schemes (e.g., 90-day standard toxic-
ity tests for pesticides in adult animals and the use of excess
offspring generated in a reproductive toxicity study for lymphocyte
phenotyping and TDAR, as described in the OECD Test Guidance
443) appear to be feasible, and will, if adopted, produce results that
can be used for immunotoxicity risk assessment. Several scenarios
on how to achieve the integrated testing approach were discussed:
1) conduct the TDAR assay at the conclusion of a 28 day or 90-day
study (AFC or ELISA approach); 2) collect serum on day 28 and
freeze and then complete standard 90-day study on the same ani-
mals. If 90-day study shows immune organ effects, then conduct
the IgM ELISA; or 3) alternatively, one could analyze 28-day serum
and, based on results, also evaluate secondary IgG anti-SRBC re-
sponse at the end of the 90-day study in the same animals. Suc-
cessful implementation of these integrated testing strategies will
reduce animal use and overall testing costs, and likely decrease
the time required to assess potential immunotoxicity.
4.2. Current considerations for application of In vitro approaches for
the assessment of immunotoxicity
Growing political and practical resistance to toxicity testing in
animals has driven the development of alternative methods for
the screening and prioritization of toxicants, including those caus-
ing immunosuppression and allergic hypersensitivity. Signiﬁcant
progress has been made in developing in vitro assays that will re-
duce animal use and testing costs while increasing throughput in
screening and prioritization efforts (dos Santos et al., 2009; Galbi-
ati et al., 2010; Martin et al., 2010). Development efforts have fo-
cused on assays to detect hypersensitivity and
immunosuppression to meet existing regulatory demands,
although assessment of DIT, immune stimulation and autoimmu-
nity are also needed (Gennari et al., 2005). Existing in vitro meth-
ods have some limitations, including the fact that they may not
capture the complex cellular interactions that take place within
the in vivo setting. In addition, the use of primary cells for
in vitro research can entail challenges and inconsistencies due to
constraints around securing human samples or the need to differ-
entiate progenitor cells. Although continuous cell lines are not the
physiological equivalents of primary cells, many have proven to be
valid surrogates but require appropriate characterization to ensure
they are accurately recapitulating the normal immunological re-
sponses and functions.
As part of the evaluation of the use of in vitromodels for assess-
ment of potential immunotoxicity, there are several overarching
factors that always need to be considered. Efforts to develop
in vitro screening assays for potential allergic contact sensitizers
were aided by the relatively limited and well-understood immuno-
logical events that lead to contact sensitization and as a result, a
number of assays are undergoing validation efforts. These include
assays to assess the ability to interact with host proteins or cells
in ways that initiate and propagate contact hypersensitivity. How-
ever, as the underlying mechanisms of chemical immunomodula-
tion are often complex and impact multiple interdependent cell
types and processes, it is likely that a battery of tests, that reﬂect
various modes of action will be required to detect and characterize
Table 3
Key events in chemical-induced skin sensitization and in vitro opportunities.
Key event In vitro Opportunities References
1. Skin penetration Human skin biopsis, pig skin; reconstituted human epidermis (Basketter et al., 2007; OECD, 2004)
2. Binding to macro-molecules
(i.e., proteins)
QSAR/Expert systems; peptide binding assay Reviewed by (Gerberick et al., 2008;
Patlewicz et al., 2007)
3. Local trauma and generation of
danger signals
KeratinoSensTM; KC activation; NCTC2544 IL-18 assay; KC gene expression proﬁle Reviewed by (Aeby et al., 2010; Corsini
and Roggen, 2009; Galbiati et al., 2010)
4. Langerhans cells maturation
and migration
DC-like up-regulation of class II antigens and costimulatory molecules, i.e., CD54,
CD86; Cytokine release, i.e., IL-8; LC-like MUTZ-3 cells migration assay; DC-like gene
expression proﬁle
Reviewed by (Casati et al., 2005; dos
Santos et al., 2009; Galbiati et al., 2010)
5. Antigen presentation to TH cells
and memory T-cell generation
In vitro T-cell activation Reviewed by (Martin et al., 2010)
D.R. Boverhof et al. / Regulatory Toxicology and Pharmacology 68 (2014) 96–107 105chemical-induced imunosuppression or immunostimulation. Be-
fore starting with in vitro tests, bioavailability should be consid-
ered. If the compound does not have appreciable bioavailability,
immunotoxicity is unlikely to occur. Furthermore, it should be rec-
ognized that in vitro systems may lack the appropriate metabolic
components that could enhance or reduce the immunotoxic poten-
tial in an in vivo system. As a general strategy, in vitro testing for
direct immunotoxicity should be done in a tiered approach. A po-
tential ﬁrst tier in this process could include measuring myelotox-
icity (bone marrow toxicity) in response to the test material of
interest. Compounds that are capable of damaging or destroying
the bone marrow will often have a profound immunotoxic effect
by limiting or eliminating immune effector cells. Therefore, if a
compound is myelotoxic the material will be a de facto immuno-
toxicant. A methodology for evaluating myelotoxicity in vitro using
bone marrow culture systems is well characterized (Haglund et al.,
2010; Pessina et al., 2001).
A negative ﬁnding in the ﬁrst tier would not necessarily be con-
clusive, because some chemicals that spare bone marrow may
damage or destroy lymphocytes, which are the primary effectors
and regulators of acquired immunity. Compounds could therefore
be tested for lymphotoxicity as part of the second tier. Toxicity
may result from the destruction of rapidly dividing cells by necro-
sis or apoptosis; alternatively, chemicals may interfere with cell
activation affecting signal transduction pathways. A variety of
methods are available for assessing cell viability (e.g., colorimetric,
ﬂow cytometric assays, etc.). After myelotoxicity and overt cyto-
toxicity are excluded as endpoints, basic immune cells functional-
ity should then be assessed by performing speciﬁc functional
assays to characterize the nature of the immunotoxic effects as
part of the third tier. Using non-cytotoxic concentrations of the
tested chemicals is an important component of these functional
evaluations (viability >80%). Table 3 presents some key targets in
chemical-induced immunosuppression and in vitro opportunities
to assess relevant immune functional parameters, including prolif-
erative responses, cytokine production, NK cell activity, and the T-
dependent antibody response or TDAR (Gennari et al., 2005; House,
2000; Koeper and Vohr, 2009). Consistent with the important role
that the TDAR plays in most regulatory guidelines described else-
where in this paper, studies have shown that the in vitro TDAR
has a high sensitivity and speciﬁcity, and is a promising assay for
the prediction of immunosuppressive properties of chemicals and
drugs (Koeper and Vohr, 2009). Moreover, Fischer et al. (2011) con-
cluded that the investigation of in vitro antibody responses is a sen-
sitive and reliable approach for detection of compound - speciﬁc
effects on the immune system, and that the implementation of this
endpoint in routine toxicology also enables reﬁnement of existing
in vivo studies by reducing the numbers of animals.
While the primary focus of this workshop was on immunosup-
pression, it is important to note that chemically-induced skin sen-
sitization potential is an endpoint that needs to be assessed within
the framework of existing and forthcoming legislation (e.g., the EUREACH regulations, the 7th Amendment to the EU Cosmetics Direc-
tive) (Corsini and Roggen, 2009), and, as a result, there has been a
lot of progress towards integrating in vitro and alternative ap-
proaches. Allergic contact dermatitis (ACD) is to a considerable ex-
tent a preventable disease. A reduction of ACD can be achieved by:
correct detection of skin sensitizers; characterization of potency;
understanding of human skin exposure; and, the application of
adequate risk assessment and management strategies. A range
of in vivo methods have been proven to be very accurate in terms
of identifying chemicals that possess skin sensitizing properties,
including the murine local lymph node assay (LLNA) (Kimber and
Weisenberger, 1989). However, the current challenge is to obtain
the same quality of information on the potency of skin sensitizing
chemicals using in silico and in vitro methods. In the last decade
important progress has resulted in the development of alternative
test methods that could make a valuable contribution to the
replacement of the existing animal models (dos Santos et al.,
2009; Galbiati et al., 2010; Luebke, 2012; Martin et al., 2010).
At present, several non-animal test methods, namely the Direct
Peptide Reactivity Assay, the KeratinoSens assay, the Myeloid U937
Skin Sensitization Test and the human Cell Line Activation Test are
under formal validation at European Centre for the Validation of
Alternative Methods (EURL-ECVAM), for their potential to predict
skin sensitization potential. The Myeloid U937 Skin Sensitization
Test has been, however, recently stopped due to transferability
problems. Results are anticipated by the end of 2013, although it
will likely take at least another 7–9 years for the full replacement
of the in vivo animal models currently used to assess sensitization
(Adler et al., 2011; Aeby et al., 2010). Another method, the THP-1
IL-8 Luc assay (Takahashi et al., 2011), is currently under validation
by the Japanese Center for the Validation of Alternative Methods,
and results are anticipated in 2013.
4.2.1. Opinions from workshop participants
Meeting participants agreed that pursuing in vitro approaches
to immunotoxicity hazard is warranted, and that published
proof-of-concept studies suggest that a number of assay methods
hold particular promise. The relatively straightforward primary
events leading to induction of allergic contact hypersensitivity
have helped to simplify the technical and theoretical aspects of as-
say design and as a result assays for this endpoint have seen good
progression. However, the complicated nature of other immuno-
toxicity responses has limited standardization of general and func-
tional assays. Overall, participants agreed that at present, in vitro
data are not suitable for risk assessment. Additional development
and evaluation of in vitro methods was deemed necessary, coinci-
dent with development and publication of immunotoxicity testing
databases that would allow for a more standardized evaluation of
the predictive value of the developing in vitro assays. When feasi-
ble, concurrent testing using in vitro and traditional in vivo meth-
ods were recommended to determine the accuracy and precision
of new methods. In addition, groups concluded that progress in
106 D.R. Boverhof et al. / Regulatory Toxicology and Pharmacology 68 (2014) 96–107developing useful in vitro approaches would be aided by experts
providing recommendations for the application and execution of
in vitro assays.5. Conclusions
Overall, the workshop provided an invaluable opportunity for
key stakeholders from government, academia and industry (both
chemical and pharmaceutical) to discuss current practices for the
assessment of immunotoxicity for environmental chemicals. Di-
verse perspectives were shared from these sectors on experiences
with the use of standard toxicology testing endpoints and func-
tional immune assays, as well as tiered-based testing strategies
and developing assays and study designs.
With respect to the concept of routine functional immunotoxic-
ity testing for environmental chemicals, participants agreed that
emerging evidence may indicate that a trigger-based approach is
appropriate, which is consistent with the experience and approach
used by the pharmaceutical industry under the ICH S8 guidance.
However, it was also recognized that deﬁned criteria need to be
established to ensure the consistent and transparent interpretation
of the potential need for additional immunotoxicity testing. Over-
all, these perspectives are supported both by a recent retrospective
analysis of 171 immunotoxicity studies (155 chemicals) that was
completed by the EPA (US EPA, 2013) and the retrospective analy-
sis from Crop Life America described above (Gehen et al., submit-
ted for publication).
With regard to DIT, participants agreed that assessment of DIT
represents a valuable means to evaluate multiple critical windows
during immune system development. Extensive discussion and
evolution in proposed DIT test approaches has occurred over the
last decade, including discussions on study design and evaluation
age. The EOGRTS represents one approach that allows for the eval-
uation of DIT as part of an integrated study design; however, the
complexity of the EOGRTS is such that requests for this assay
should only be made after careful consideration of the study objec-
tives and needs.
With respect to integrating functional immunotoxicity end-
points into standard adult rodent repeat dose studies (Ladics
et al., 1998; Ladics et al., 1995), participants agreed that this ap-
proach should be considered as appropriate for fulﬁlling any
immunotoxicity testing requirements, while also maximizing
information collection and reducing overall animal use.
Participants also recognized the signiﬁcant efforts in the area of
in vitro approaches for evaluating toxicity, along with the numer-
ous factors that continue to drive research in this area. In the case
of immunotoxicity, considerable advancements have been made
with in vitro testing approaches for contact sensitization, as com-
pared to in vitro assays for immunosuppressant hazard identiﬁca-
tion. Efforts to develop reliable alternative methods to identify
contact sensitizers have beneﬁtted from the knowledge and com-
partmentalization of key steps in the development of skin sensiti-
zation, whereas assays for immunosuppression will need to
address multiple complex pathways. This realization is consistent
with the opinions of an OECD immunotoxicity workgroup report
on alternative testing methods for immunotoxicity assessment
that is nearing ﬁnalization.
An active dialog among toxicologists continues regarding po-
tential opportunities to change our approaches to chemical hazard
characterization and risk assessments (Andersen and Krewski,
2010; Patlewicz and Lander, 2013). In the case of pesticides, cur-
rent registration requirements involve the completion of a sub-
stantial number of toxicity studies. As additional experience is
gained with current testing requirements and as new assays and
technologies are developed that can advance our testingapproaches, it is critical for all stakeholders to engage in active dia-
log about potential opportunities to advance our current testing
approaches to increase efﬁciency while maintaining the utility of
the data for hazard identiﬁcation and risk assessment. The infor-
mation shared and the discussions that took place during this
workshop have provided an important exchange that will help to
shape the future of immunotoxicity testing for environmental
chemicals.
6. Disclaimers
This article may be the work product of an employee or group of
employees of the National Institute of Environmental Health Sci-
ences (NIEHS), National Institutes of Health (NIH), however, the
statements, opinions or conclusions contained therein do not nec-
essarily represent the statements, opinions or conclusions of
NIEHS, NIH or the United States government.
This report has been reviewed by the Environmental Protection
Agency’s Ofﬁce of Research and Development and Ofﬁce of Pesti-
cides Programs, and approved for publication. Approval does not
signify that the contents necessarily reﬂect the views and policies
of the Agency nor does mention of trade names or commercial
products constitute endorsement or recommendation for use.
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